Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 10/20 | 0.51 |
| ▸ | MEN1 | O00255 | 9/20 | 0.51 |
| ▸ | GAA | P10253 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | DHODH | Q02127 | 1/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.43 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3337610 | 0.82 | KMT2A (0.59) | KMT2AMEN1GAANPC1RAB9A | |
| SCHEMBL3341333 | 0.77 | KMT2A (0.42) | KMT2AMEN1GAAHTTLMNA | |
| SCHEMBL3605366 | 0.74 | MEN1 (0.48) | KMT2AMEN1GAANPC1RAB9A | |
| SCHEMBL3795985 | 0.74 | MAPT (0.52) | KMT2AMEN1RAB9ALMNAMAPT | |
| Bromide SCHEMBL11255859 | 0.73 | MEN1 (0.48) | KMT2AMEN1GAANPC1RAB9A | |
| SCHEMBL3338327 | 0.72 | KDM4E (0.61) | KMT2AMEN1GAANPC1RAB9A | |
| SCHEMBL7144161 | 0.71 | ATG4B (0.53) | KMT2AMEN1GAANPC1RAB9A | |
| Bromide SCHEMBL7143173 | 0.69 | MYC (0.61) | KMT2AMEN1GAANPC1RAB9A | |
| SCHEMBL10377412 | 0.68 | ALDH1A1 (0.46) | KMT2AMEN1GAANPC1RAB9A | |
| SCHEMBL10375532 | 0.68 | KMT2A (0.51) | KMT2AMEN1GAANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410152-B2 | Thiazolhydrazides for treatment of neurodegenerative diseases | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E. V. (DE) | 2013-04-02 | — | — | US | disclosed |
| US-20100151064-A1 | THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES | TECHNISCHE UNIVERSITAT DARMSTADT (DE) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100151064-A1 | THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES | HTT, MAPT, SNCA | KMT2A 3492/4885MEN1 1886/4885GAA 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.